In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Meeting to be held in Denver on March 10 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Docebo (NASDAQ:DCBO – Get Free Report) had its target price lowered by research analysts at Scotiabank from $55.00 to $45.00 ...

Fintel reports that on February 28, 2025, Craig-Hallum initiated coverage of MediWound (NasdaqGM:MDWD) with a Buy ...

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...

We recently compiled a list of the 10 Worst Performing IT Services Stocks to Buy According to Analysts. In this article, we are going to take a look at where TechTarget, Inc.

Fintel reports that on February 20, 2025, Craig-Hallum downgraded their outlook for Axon Enterprise (NasdaqGS:AXON) from Buy ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55 ...

ACM Research rocketed more than 20% by afternoon trading on Wednesday following its fourth quarter 2024 financial results ...

As previously reported, Craig-Hallum downgraded Akamai (AKAM) to Hold from Buy with a $90 price target citing several surprises in the company’s “disappointing” FY25 guide. As the firm ...